Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study

Vaz-de-Melo, Renan Oliveira; Giollo-Júnior, Luiz Tadeu; Martinelli, Débora Dada; Moreno-Júnior, Heitor; Mota-Gomes, Marco Antônio; Cipullo, José Paulo; Yugar-Toledo, Juan Carlos; Vilela-Martin, José Fernando.
São Paulo med. j ; 132(5): 290-296, 08/2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-721013

Documentos relacionados

  1. Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study.
  2. Nebivolol: an endothelium-friendly selective ß1-adrenoceptor blocker.
  3. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial.
  4. [Clinical-hemodynamic and anti-ischemic effects ivabradine and nebivolol ischemic heart disease with left ventricular dysfunction].
  5. Successful treatment of intravascular papillary endothelial hyperplasia (IPEH) by the beta-adrenergic antagonist nebivolol.
  6. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow.
  7. Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study.
  8. Nebivolol ameliorates nitric oxide deficient hypertension.
  9. [Prospective follow-up of nebivolol in the treatment of arterial hypertension].
  10. Nebivolol: a third-generation beta-blocker for hypertension.